US Physical Therapy (NYSE: USPH) reported earnings on Nov. 8. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), US Physical Therapy met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue grew and GAAP earnings per share expanded.

Margins expanded across the board.

Revenue details
 US Physical Therapy reported revenue of $62.9 million. The five analysts polled by S&P Capital IQ hoped for a top line of $63.8 million on the same basis. GAAP reported sales were 5.3% higher than the prior-year quarter's $59.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.38. The five earnings estimates compiled by S&P Capital IQ anticipated $0.38 per share. GAAP EPS of $0.38 for Q3 were 12% higher than the prior-year quarter's $0.34 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 26.5%, 100 basis points better than the prior-year quarter. Operating margin was 15.0%, 50 basis points better than the prior-year quarter. Net margin was 7.3%, 40 basis points better than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $63.6 million. On the bottom line, the average EPS estimate is $0.35.

Next year's average estimate for revenue is $254.2 million. The average EPS estimate is $1.52.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 245 members out of 249 rating the stock outperform, and four members rating it underperform. Among 72 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 70 give US Physical Therapy a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on US Physical Therapy is outperform, with an average price target of $30.83.